Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells 58,253 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CEO Michael Davidson sold 58,253 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $35.30, for a total transaction of $2,056,330.90. Following the completion of the transaction, the chief executive officer owned 459,859 shares in the company, valued at approximately $16,233,022.70. The trade was a 11.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS traded down $0.73 during trading on Thursday, reaching $34.28. 900,936 shares of the company were exchanged, compared to its average volume of 634,742. The firm has a market capitalization of $3.89 billion, a PE ratio of -19.81 and a beta of 0.06. The business’s fifty day simple moving average is $34.05 and its 200-day simple moving average is $32.88. NewAmsterdam Pharma Company N.V. has a 12-month low of $14.06 and a 12-month high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.23). The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%. On average, sell-side analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Stifel Nicolaus lifted their price objective on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Royal Bank Of Canada increased their price objective on NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Needham & Company LLC lifted their target price on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. HC Wainwright upgraded NewAmsterdam Pharma to a “strong-buy” rating in a research report on Thursday, February 19th. Finally, Guggenheim increased their price target on NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $47.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NAMS. Seven Fleet Capital Management LP acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $140,000. Empowered Funds LLC acquired a new stake in NewAmsterdam Pharma during the 4th quarter worth $85,000. XTX Topco Ltd grew its holdings in shares of NewAmsterdam Pharma by 1,714.1% during the fourth quarter. XTX Topco Ltd now owns 137,492 shares of the company’s stock worth $4,823,000 after buying an additional 129,913 shares in the last quarter. Virtus Investment Advisers LLC raised its position in shares of NewAmsterdam Pharma by 32.0% in the fourth quarter. Virtus Investment Advisers LLC now owns 7,142 shares of the company’s stock valued at $251,000 after buying an additional 1,731 shares during the last quarter. Finally, Twinbeech Capital LP purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter worth about $961,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.